ArticleExpert opinion on drug discovery2025
The potential of academic drug discovery: successes and challenges.
Matthew Stremlau, Barbara S Slusher
Abstract readEditorial
In one paragraphArticle in Expert opinion on drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
2 authors.
Matthew StremlauJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, USA.
Barbara S SlusherJohns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, USA.
Funding
Therapeutic CoreP30MH075673 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Leah Helane Rubin · 2006 to 2026
$33.2MJohns Hopkins Institute for Clinical and Translational ResearchUM1TR004926 · NCATS · JOHNS HOPKINS UNIVERSITY · PI STEPHEN N. DAVIS, Daniel Ernest Ford · 2024 to 2026
$28.5MTargeting glutamate carboxypeptidase in perinatal brain injuryR01NS093416 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Sujatha Kannan, Kannan Rangaramanujam · 2016 to 2026
$4.8MGlutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activityR01AI155602 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES · 2020 to 2024
$4.0MDevelopment of GCPII inhibitors for the treatment of age-related cognitive disordersR01AG068130 · NIA · JOHNS HOPKINS UNIVERSITY · PI ARNSTEN, AMY F.T., SLUSHER, BARBARA STAUCH · 2020 to 2024
$3.8MEvaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of CancersR01CA282475 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Robert Blelloch, Rana Rais · 2024 to 2026
$3.4MDevelopment of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's diseaseR01AG084728 · NIA · JOHNS HOPKINS UNIVERSITY · PI Rana Rais, Barbara Stauch Slusher · 2023 to 2026
$2.8MMacrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopeniaR01AG078181 · NIA · JOHNS HOPKINS UNIVERSITY · PI Ahmet Hoke, Kannan Rangaramanujam · 2022 to 2026
$2.7MTargeting age and gender-dependent microglia-mediated mechanisms underlying postoperative cognitive impairment for treatment of delirium in the elderlyR01AG065168 · NIA · JOHNS HOPKINS UNIVERSITY · PI KAMIYA, ATSUSHI · 2020 to 2024
$2.1MTraining in Neurotherapeutics for Academic ScientistsR25NS129110 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MICHAEL A. ROGAWSKI, Barbara Stauch Slusher · 2022 to 2026
$1.3MMicroglia-targeted glutaminase inhibition forthe treatment of chronic stress-associated depressionR56MH135895 · NIMH · JOHNS HOPKINS UNIVERSITY · PI ZHU, XIAOLEI · 2024 to 2025
$1.1MNCATS NIH HHS UM1 TR004926NCI NIH HHS R01 CA282475NIAID NIH HHS R01 AI155602NIA NIH HHS R01 AG065168NIA NIH HHS R01 AG068130NIA NIH HHS R01 AG078181NIA NIH HHS R01 AG084728NIMH NIH HHS P30 MH075673NIMH NIH HHS R56 MH135895NINDS NIH HHS R01 NS093416NINDS NIH HHS R25 NS129110
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Academic Drug Discovery Centers (ADDCs)aI-based drug discoverychallenging targetsdiversified fundingearly-stageemerging drug discovery technologyindustry-academia partnershipssmall moleculestranslational researchunderserved therapeutic areas
Identifiers
PMID40592780
PMCPMC12482104
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390